Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oric Pharmaceuticals (ORIC) Other Accumulated Expenses (2019 - 2026)

Oric Pharmaceuticals filings provide 8 years of Other Accumulated Expenses readings, the most recent being $875000.0 for Q1 2026.

  • Quarterly Other Accumulated Expenses fell 25.6% to $875000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $875000.0 through Mar 2026, down 25.6% year-over-year, with the annual reading at $866000.0 for FY2025, 31.41% up from the prior year.
  • Other Accumulated Expenses hit $875000.0 in Q1 2026 for Oric Pharmaceuticals, up from $866000.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $1.2 million in Q1 2025 and bottomed at $371000.0 in Q3 2022.
  • Average Other Accumulated Expenses over 5 years is $754588.2, with a median of $797000.0 recorded in 2023.
  • The largest annual shift saw Other Accumulated Expenses tumbled 66.95% in 2022 before it skyrocketed 94.77% in 2024.
  • Oric Pharmaceuticals' Other Accumulated Expenses stood at $695000.0 in 2022, then grew by 14.68% to $797000.0 in 2023, then fell by 17.31% to $659000.0 in 2024, then surged by 31.41% to $866000.0 in 2025, then grew by 1.04% to $875000.0 in 2026.
  • Per Business Quant, the three most recent readings for ORIC's Other Accumulated Expenses are $875000.0 (Q1 2026), $866000.0 (Q4 2025), and $898000.0 (Q3 2025).